Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass?
Peeters et al. 20081
Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium
Primary patency of GORE® PROPATEN® Vascular Graft
Patient characteristics
Characteristic | N | % |
---|---|---|
Rutherford classification | ||
3 | 85 | 56% |
4 | 29 | 19% |
5 | 39 | 26% |
Vessel runoff | ||
0 | 7 | 5% |
1 | 76 | 50% |
2 | 43 | 28% |
3 | 27 | 18% |
Hypertension | 88 | 64% |
Diabetes | 37 | 27% |
Renal insufficiency | 12 | 9% |
BK fem-pop | 41 | 53% |
Infrapopliteal | 37 | 47% |
TP trunk | 11 | 30% |
Anterior tibial | 10 | 27% |
Posterior tibial | 10 | 27% |
Peroneal | 6 | 16% |
Study details
- Prospective, non-randomized, multi-center study
- No adjunctive techniques (patches or cuffs) were used in the study
- The 3-year secondary patency rate for below-knee fem-pop and infrapopliteal bypasses were 80% and 62%, respectively
- The 3-year limb salvage rate for all CLI patients was 86%*
Propaten® Vascular Graft [GORE® PROPATEN® Vascular Graft] may succeed in bridging the gap between venous and regular PTFE bypass...especially for infrapopliteal bypasses. — P. Peeters
* Limb salvage rates are for both above-knee and below-knee bypasses.
1. Peeters P, Verbist J, Deloose K, Bosiers M. Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass? Italian Journal of Vascular & Endovascular Surgery 2008;15(3):143-148.